# US 2022/0064285 A1 · Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064285 A1
- Document ID: US20220064285A1
- Status: Published application
- Kind: A1
- Application number: 17/418,343
- Filed: 2019-12-27
- Published: 2022-03-03
- Earliest claimed: 2018-12-28
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: David Lagares
- Web page: https://patentgrep.com/patent/US20220064285A1

## CPC

- A61B 5/4839: {combined with drug delivery}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61B 5/4842: {Monitoring progression or stage of a disease}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods and compositions for treating organ fibrosis using antibodies or antigen-binding fragments thereof that bind to and block the soluble Ephrin B2 ectodomain.

## Claims

### Claim 1

A method for treating organ fibrosis in a subject, comprising:
identifying a subject who has organ fibrosis, and administering a therapeutically effective amount of one or more antibodies or antigen binding fragments thereof that bind to and block soluble ephrin-B2 ectodomain.

### Claim 2 (depends on 1)

The method of claim 1, wherein the organ fibrosis is pulmonary, skin, kidney fibrosis, liver fibrosis or cirrhosis, systemic sclerosis, or desmoplastic tumors.

### Claim 3 (depends on 1)

The method of claim 1, wherein the treatment results in a reduction in fibrosis and/or a return or approach to normal function of the organ.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has pulmonary fibrosis, and the therapeutically effective amount results in decreased lung fibrosis and improved lung function.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has pulmonary fibrosis.

### Claim 6 (depends on 5)

The method of claim 5, wherein the subject has patterns of fibrosis on a chest radiograph or chest computed tomography (CT) or high-resolution CT (HRCT) scan, and bibasilar inspiratory crackles.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject has systemic sclerosis.

### Claim 8 (depends on 7)

The method of claim 7, wherein the subject has skin thickening of the fingers, finger tip lesions, telangiectasia, abnormal nailfold capillaries, interstitial lung disease or pulmonary arterial hypertension, Raynaud's phenomenon, and SSc-related autoantibodies.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject has liver fibrosis or cirrhosis.

### Claim 10 (depends on 9)

The method of claim 9, wherein the subject has fibrosis detected on biopsy or imaging.

### Claim 11 (depends on 1)

The method of claim 1, wherein the antibody is a clone B11 antibody.

### Claim 12 (depends on 1)

The method of claim 1, wherein the antibody is a clone 2B1 antibody.

### Claim 13 (depends on 1)

The method of claim 1, wherein the antibody is a monoclonal chimeric, de-immunized or humanized antibody.

### Claim 14 (depends on 2)

The method of claims 2, wherein the pulmonary fibrosis is idiopathic pulmonary fibrosis.